Biomedical Engineering Reference
In-Depth Information
Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007;370:
1543-1551.
[5] Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A,
Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine
candidate Plasmodium falciparum apical membrane antigen 1 and induction of
antibodies that inhibit erythrocyte invasion. Infect Immun 2002;70:4471-4476.
[6] Miles AP, Zhang Y, Saul A, Stowers AW. Large-scale purification and characterization of
malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Expr Purif
2002;25:87-96.
[7] ICH. Draft consensus guideline, pharmaceutical development annex to Q8, current Step 2
version. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, 2007.
[8] Yu LX. Pharmaceutical quality by design: product and process development, understanding,
and control. Pharm Res 2008;25:781-791.
[9] Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10.
[10] Shields RL, Lai J, KeckR, O'Connell LY, HongK,MengYG,Weikert SH, Presta LG. Lack of
fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII
and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-26740.
[11] Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB,
Schneerson R. Long-lasting and transmission-blocking activity of antibodies to Plasmodium
falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci USA
2007;104:293-298.
[12] Tsai CW, Duggan PF, ShimpRL Jr, Miller LH, NarumDL. Overproduction of Pichia pastoris
or Plasmodium falciparum protein disulfide isomerase affects expression, folding and
O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris.
J Biotechnol 2006;121:458-470.
[13] Darko CA, Angov E, CollinsWE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS,
Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA. The clinical-grade 42-kilodalton
fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in
Escherichia coli protects Aotus nancymai against challenge with homologous
erythrocytic-stage parasites. Infect Immun 2005;73:287-297.
[14] Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria
vaccine candidate in review. Trends Parasitol 2008;24:74-84.
[15] SimBK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH. Receptor and ligand domains for
invasion of erythrocytes by Plasmodium falciparum. Science 1994;264:1941-1944.
[16] Narum DL, Haynes JD, Fuhrmann S, Moch K, Liang H, Hoffman SL, Sim BK. Antibodies
against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion
pathways that do not involve sialic acids. Infect Immun 2000;68:1964-1966.
[17] Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, Haynes JD, Moch JK,
Lucas C, Luu T, Magill AJ, Hoffman SL, Sim BK. Protection of Aotus monkeys by
Plasmodium falciparum EBA-175 region II DNA prime-protein boost
immunization
regimen. J Infect Dis 2001;183:303-312.
[18] SimBK, NarumDL, Liang H, Fuhrmann SR, Obaldia N 3rd, Gramzinski R, Aguiar J, Haynes
JD, Moch JK, Hoffman SL. Induction of biologically active antibodies in mice, rabbits, and
monkeys by Plasmodium falciparum EBA-175 region II DNAvaccine. Mol Med 2001;7:247-
254.
